FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody that specifically binds to mesothelin. Also disclosed is a nucleic acid encoding the said antibody, an expression vector and a host cell containing the said nucleic acid; a chimeric antigen receptor containing the said antibody; an immunoconjugate and a pharmaceutical composition containing the said antibody. The use of this antibody is disclosed.
EFFECT: invention makes it possible to effectively treat tumors associated with mesothelin.
32 cl, 10 dwg, 4 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES BINDING MESOTHELIN AND CD137 | 2019 |
|
RU2815066C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| MESOTHELINIC CAR RECEPTORS AND USE THEREOF | 2020 |
|
RU2822193C2 |
| GLYPICAN-3 ANTIBODY AND USE THEREOF | 2016 |
|
RU2744245C2 |
| ANTIBODY TO IL-13RA2 AND ITS APPLICATION | 2018 |
|
RU2756623C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
